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INTRODUCTION
In utero hematopoietic stem cell (HSC) transplantation
for inherited diseases has the potential to avoid many of the
problems of postnatal transplant. The early gestation fetus is
immunologically immature and susceptible to tolerance
induction by foreign antigens [1,2]. Thus, myeloablative
immunosuppression may not be necessary for early gesta-
tion prenatal allogeneic HSC transplantation. In addition, in
utero HSC transplant can, in theory, be performed before
the underlying disease produces major organ damage [3].
This is particularly important for diseases such as the
leukodystrophies, for which transplants, to be efficacious,
must be done before the development of significant neuro-
logical damage [4,5].
Besides our prior report [6], 20 other in utero HSC
transplants have been reported for the treatment of a variety
of congenital lymphohematopoietic diseases or inborn
errors of metabolism [3,6–16]. Unfortunately, success has
been achieved in only four fetuses, all among the five
patients with immunodeficiency diseases (bare lymphocyte
syndrome or severe combined immunodeficiency disease
[SCID]). Only lymphoid cell engraftment was detected in
these patients with cellular immunodeficiency disorders in
which normal donor lymphocytes have a survival advantage
over the diseased host lymphocytes [9,13,16,17]. In the 15 in
utero transplant cases reported for diseases other than
immunodeficiency disorders, no therapeutic engraftment of
the donor stem cells was detected at abortion or after birth.
This low incidence of engraftment is probably the result of
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ABSTRACT
To date, 16 in utero hematopoietic stem cell (HSC) transplants for diseases other than immunodeficiency disorders
have been reported. No therapeutic level of engraftment was detected in 15 of these transplants. To overcome
engraftment failure, we transplanted a very large number (5 billion paternal CD341 cells/kg) of HSCs to a fetus with
leukodystrophy during the first trimester of gestation. As reported previously, the fetus died in utero 7 weeks after
the procedure and the cause of death appeared to be overwhelming donor engraftment. In the present investigation,
we developed a human–murine chimera model to test for the optimal donor cell dose for human in utero transplan-
tation. We found a strong correlation between the level of donor engraftment in three human fetuses transplanted
for leukodystrophy during the first trimester of gestation and the results of parallel xenotransplants of the same
human donor cells using the NOD/SCID mouse model. This small animal model appears to predict both extremes
of hyperengraftment (seen in the first human fetus transplanted) and engraftment failure (seen in the second and
third human fetuses transplanted in utero). These and future correlated clinical and laboratory assay results may be
useful for the development of in utero transplants for a variety of congenital disorders.
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performing the HSC transplant procedure relatively late in
gestation (.16 weeks gestation, after significant fetal
immunocompetence has developed) [18,19] or transplanting
insufficient numbers of donor HSCs [3,6] or both. Current-
ly, chorionic villus sampling may be safely performed at
10–12 weeks gestation, thus allowing genetic diagnosis and
in utero transplant in the first trimester. The process of
CD341 cell selection makes it possible to concentrate large
numbers of HSCs in very small volumes and simultaneously
reduces the number of T cells in the donor graft; this would
allow transplant of larger HSC doses to the tiny first
trimester fetus (approximately ,30 g). 
We have performed in utero HSC transplantation with
no myeloablation for three fetuses with globoid cell
leukodystrophy, and reported on one of these [6]. Trans-
plantation was performed at 13.5 weeks gestation in each
case. Haploidentical paternal donors were used, in part to
avoid general anesthesia for bone marrow harvesting from
the pregnant mother. The first fetus was transplanted with 5
billion paternal CD341 cells/kg, but died in utero 7 weeks
after the procedure [6]. The cause of death appeared to be
overwhelming donor engraftment, with leukostasis and
paternal (donor) myeloid cells infiltrating most tissues
examined including liver, spleen, skin, epicardium, lungs,
and kidneys. The fetal liver (the major site of hematopoiesis
in the second trimester fetus) was essentially replaced by
donor cells. The outcome in this and the other clinical cases
highlights the need to search for the ideal dose and source
of HSCs for in utero transplants [3,11,14].
At present, limited in vivo assays of human cell engraft-
ment potential are available [20]. One such assay is the
human-sheep model in which human HSCs are transplanted
into a fetal lamb between days 50 and 60 of a 5-month sheep
gestation [21,22]. Because of the relative immuno-incompe-
tence of early gestation fetal sheep, this results in long-term
mixed human–sheep chimerism in multiple hematopoietic
lineages. However, scarcity and cost limit the number of ani-
mals per experiment in this model. As an alternative model,
hematopoietic chimeras in immunodeficient mice provide a
small animal assay for human HSCs [20,23–25]. In particu-
lar, high levels (up to 90%) of donor human cells have been
observed using the nonobese diabetic/LtSz-scid/scid
(NOD/SCID) mice [20,24]. These mice have defects in nat-
ural killer cell activity, as well as defective macrophage and
complement function on a severe T- and B-lymphoid–
immunodeficient background [26]. The size (,20–30 g) and
immune status of a 6- to 8-week-old sublethally irradiated
(350 cGy) NOD/SCID mouse is somewhat similar to that of
a human fetus at 13 weeks of gestation [27]. Here, we report
the clinical course of our second and third transplanted
human fetuses, with results of parallel transplant studies
using the NOD/SCID mouse model.
MATERIALS AND METHODS
Transplantation of human cells into NOD/SCID mice
Surplus CD341 cells from the first and second paternal
donors were transplanted by tail-vein injection into seven
sublethally irradiated (350 cGy using 137Cs g-irradiator) 6-
to 8-week-old NOD/SCID mice [20]. All mice received
human interleukin (IL)-3, granulocyte-macrophage colony-
stimulating factor (GM-CSF), granulocyte colony-stimulat-
ing factor (G-CSF), and stem cell factor (SCF; 10 m g of
each/dose) intraperitoneally every Monday, Wednesday, and
Friday posttransplantation. Mice were bred and maintained
in pathogen-free conditions, as described [25]. Animal
Figure 1. Flow cytometric analysis of human–murine chimeras
(A) The percentages of human cells in the marrow or spleen were enumerated by flow cytometry as cells labeled with the anti-human CD45 PE-Cy5 monoclonal
antibody (mAb) but not anti-mouse CD45 FITC mAb (R1). The number of human CD341 cells transplanted and the organ analyzed is shown above the corre-
sponding dot plot. (B) Immunophenotypes of the (human) cells in R1 from the marrow of the chimera that had received 5 billion human CD341 cells/kg are
shown. Isotype control mAbs were used to assess non-specific staining.
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experiments were approved by the Animal Care and Use
Committee of the Johns Hopkins Medical Institutions.
Analysis of human cell engraftment in human–murine
chimeras
Single-cell suspensions were prepared from removed
spleens. Bone marrow cells were obtained by flushing both
the removed femurs and tibiae from each animal. Cells were
counted using a Coulter Z1 cell counter (Coulter, Miami,
FL). Human cells were enumerated and cell lineages deter-
mined by three-color flow cytometry (fluorescence-activated
cell sorter [FACS], Becton Dickinson, San Jose, CA) using
murine monoclonal anti-human leukocyte antibodies, as
described previously (Fig. 1) [20,22,25]. Colony-forming
assays were performed using described methods [25], which
were shown to be selective for the growth of human
colonies in a murine cell background.
RESULTS
Second recipient
The second family was referred to our institution after
prenatal testing at 10 weeks gestation diagnosed their fetus
as having globoid cell leukodystrophy (lacking galactocere-
brosidase activity). Written informed consent for in utero
HSC transplant, as approved by the Joint Committee for
Clinical Investigation of the Johns Hopkins University and
by the Food and Drug Administration (IND #5790), was
obtained. The gestational age of the fetus at transplant was
13 weeks and 3 days by dates and was confirmed by obstetri-
cal sonography. A full marrow harvest from the fetus’ father
yielded 30 billion nucleated cells (1.3% CD341 stem/pro-
genitor cells by flow cytometry, Becton Dickinson FACSort)
[25] and the mononuclear cell preparation contained 5 bil-
lion cells (4.9% CD341 and 43% CD31 T cells). CD341
cell selection was performed, as described previously [6].
The CD341 cell preparation contained 250 million cells
(84% CD341 and 7% CD31). We decided empirically to
transplant 0.5 billion CD341 cells/kg to this fetus, i.e., 1 log
fewer CD341 cells compared with the number of cells trans-
planted to the first fetus, which died with overwhelming
donor engraftment. Thus, 10 million CD341 cells were
concentrated into 0.5 mL (phosphate-buffered saline con-
taining 1% human serum albumin) and infused under ultra-
sound guidance transabdominally through the mother into
the peritoneal cavity of the fetus using a 22-gauge spinal
needle. Fetal heart rate and activity did not change before or
after the procedure. A small leakage of amniotic fluid was
noted 1 hour after the procedure, with mild oligohydram-
nios noted by ultrasound. The amniotic fluid volume the
following morning was normal and remained so until the
time of delivery. Weekly sonograms were unremarkable with
normal fetal growth. At 37 weeks, mild oligohydramnios
was noted and a healthy-appearing male infant weighing 
8 lbs 1 oz was delivered by repeat Cesarean section.
Restriction fragment length polymorphism analysis [6]
of immunoaffinity-separated umbilical cord blood CD51
T-lymphoid cells and CD191 B-lymphoid cells obtained at
birth showed that 2% of these cells were of paternal (donor)
origin. No leukocyte galactocerebrosidase [28] was detected
in the cord blood. At 2 months of age, nerve conduction
velocity was .2 standard deviations below the mean and
protein concentration in the cerebrospinal fluid was 124
mg/dL (normal ,40 mg/dL). Thus, the in utero transplant
failed to engraft significantly or cure the disease. Mixed
lymphocyte cultures showed that the infant could not toler-
ate paternal cells. A postnatal HSC transplant [28] from a
human leukocyte antigen (HLA)-matched unrelated donor
was performed for this baby at 4 months of age (July 1998).
One month after transplantation, the protein concentration
in the cerebrospinal fluid (45 mg/dL) and the leukocyte
galactocerebrosidase activity (12 nmol · hr–1 · mg–1 protein)
were normal [28].
Third recipient
The third transplantation was performed on the second
affected fetus of the first couple (whose first fetus died of
overengraftment after in utero bone marrow transplantation,
as described above) [6]. In utero transplantation was per-
formed at 13.5 weeks gestation. Ten million paternal cells
(0.5 billion cells/kg fetal weight, 88% CD341, 4% CD31)
were infused intraperitoneally, as described above. The pro-
cedure and the remainder of the pregnancy were uncompli-
cated. A healthy-appearing male infant was delivered at 40
weeks of gestation ( June 1998). Restriction fragment length
polymorphism analysis of umbilical cord blood cells
obtained at birth showed that none of these cells were of
paternal (donor) origin. No leukocyte galactocerebrosidase
was detected in the cord blood. Our current plan for this
baby is to perform a postnatal HSC transplant.
Human–murine chimera model
We performed full-quantity paternal marrow harvests,
since such large numbers of total cells were necessary for
the CD341 cell selection device [6]. Using all the available
surplus CD341 cells from the paternal donors, selected
Table 1. Human cell engraftment
Source of Cell dose to CD341 CD31 Number Human CD451 cells Paternal cells in
CD341 cells recipient (109/kg) (%) (%) of mice in chimeras' marrows (%) fetal recipient (%)
lst paternal donor 5 91 5 ND ND 100 in livera (1st recipient)
2nd paternal donor 5 84 7 1 97 ND
0.5 — — 2 ,1, 2.5 2 in cord blood (2nd recipient)
0.25 — — 2 0, 1.5 ND
1st paternal donor 0.5 88 4 2 0, 0 0 in cord blood (3rd recipient)
aLiver is the primary hematopoietic organ in a second trimester fetus [12]. ND, not done.
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doses of human CD341 cells were
transplanted by tail-vein injection
into sublethally irradiated (350 cGy using a 137Cs g-irradia-
tor) 6- to 8-week-old NOD/SCID mice (Table 1). One
mouse was injected intravenously with 5 billion CD341
cells/kg, the dose of CD341 cells transplanted to the first
fetus (reported earlier), which died of overwhelming donor
cell engraftment [6]. Four mice were injected with 0.5 bil-
lion CD341 cells/kg, the dose of CD341 cells transplanted
to the fetuses described herein. Additionally, two mice were
transplanted with 0.25 billion CD341 cells/kg.
At 7 weeks after transplantation, the mouse that had
received 5 billion human donor CD341 cells/kg was clearly
moribund with pallor, weight loss, hair loss, and a humped
back. The mouse’s body weight had dropped to 13 g from
20 g at transplant. The mouse was killed. Its spleen was of
normal size and yielded 60 million leukocytes. The thymus
was not enlarged. The marrow (from
both femurs and tibiae combined)
yielded 36 million leukocytes. Examination indicated that
97% of the marrow cells and 99% of the spleen cells
expressed human CD45 (common leukocyte antigen), but
not murine CD45 (Table 1 and Fig. 1A). Most of the
human cells expressed CD15 (granulocytic) and some
expressed CD19 (pan-B lymphoid) or CD8 (T suppressor)
leukocyte differentiation antigens (Fig. 1B ). A total of 1, 3,
4, and 6 thousand human multipotent colony-forming
units, colony-forming units granulocyte macrophage,
burst-forming units-erythroid, and colony-forming units-
erythroid, respectively, were found in the chimeric marrow
from both femurs and tibiae. Tissue immunostains con-
firmed that virtually all cells in this chimera’s marrow and
spleen were human leukocytes. Infiltration of human
hematopoietic cells was also demonstrated in many other
tissues examined including liver, lungs, and kidneys. The
mouse appears to have died of fulminant sepsis and multi-
ple hemorrhages (Fig. 2). There was no histologic evidence
of graft-vs.-host disease (GVHD; Figs. 2E and F) [25].
All other mice, which were transplanted with lower
doses (0.25 or 0.5 billion CD341 cells/kg) of human cells,
appeared well at the time of death, 8 weeks after transplan-
tation. No or low levels of human cells (0–2.5%) were
detected in the marrows (Table 1 and Fig. 1A) and no
human cells were detected in the spleens of these six mice.
DISCUSSION
These results indicate a strong correlation between the
levels of donor hematopoietic engraftment observed in these
three human fetuses transplanted in utero with paternal
CD341 cells at 13.5 weeks of gestation and the levels of
engraftment of human cells (derived from the same donor
cell preparations) detected in the human–murine chimera
model. Transplan-
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donor cell engraftment in 2 of 2
human fetuses and in 4 of 4
human–murine chimeras. The mouse that received 5 billion
human CD341 cells/kg exhibited hemorrhage and sepsis,
likely due to severe suppression of murine thrombopoiesis
and granulocytopoiesis. The donor HSCs appear to have
outcompeted endogenous host (murine) hematopoiesis (Fig.
1A). How-ever, conditions in these mice do not support
human thrombopoiesis and result in low levels of mature
human myeloid cells in the peripheral circulation [23].
This small-animal model appears to predict both
extremes of multilineage hyper-engraftment and engraft-
ment failure in human in utero transplant. Because limited
numbers of surplus cells from the paternal full harvest were
available for testing, it was impossible to perform a detailed
study of the dose-response relationship for intermediate
doses between 0.5 and 5 billion CD341 cells/kg. However,
we and others previously reported using cells pooled from
several donors, a dose-response relationship between the
number of human cells (from cord blood, bone marrow, or
mobilized blood) transplanted into NOD/SCID mice, and
the number of human CD451 cells engrafted in their mar-
rows or spleens [20,29]. Taken together, our results suggest
an increase in engraftment with higher numbers of HSCs.
Thus, the optimal dose of CD341 cells from a paternal
donor for in utero transplantation of a fetus with leukodys-
trophy at 13–14 weeks of gestation appears to lie between
0.5 and 5 billion CD341 cells/kg. Compared with human
immunodeficiency disorders, a higher dose may be needed
for diseases such as leukodystrophies in which normal donor
cells have no survival advantage over the diseased cells. This
hypothesis is supported by the clinical observations that suc-
cessful in utero transplants (with single-lineage engraftment),
thus far, have only been achieved for immunodeficiency dis-
eases [3,13,16]. However, further work is necessary before
absolute recommendations can be made, and each disease
Figure 2. Autopsy findings of the human–murine chimera that had received 5 billion human CD341 cells/kg
(A) Spleen, extensive infiltration of human myeloid and lymphoid cells; (B) brain, multiple acute hemorrhagic areas ranging from 0.1–1 mm in diameter; 
(C) lung, multifocal areas of coagulative necrosis with dense bacterial emboli; (D) kidney, multifocal areas of tubular degeneration with bacterial emboli; 
(E) liver, dense infiltration of human myeloid cells around portal tracts mixed with very few lymphocytes; (F) stomach (non-secretory part), multiple bacterial
colonies and the absence of lymphocytic infiltration in the gastric mucosa.
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may have unique biological aspects to be considered.
Our findings are contradictory to the saturation kinet-
ics model [14], which suggests that donor cell engraftment
cannot be increased dramatically by increasing the dose of
donor cells in a single administration. The saturation
kinetics model proposes that donor cell engraftment is lim-
ited by the number of receptive sites available at a particu-
lar point in time. This model predicts that repetitive trans-
plants [13,16], which would allow for development of new
niches in the fetus, may be necessary to increase the level
of engraftment. However, results from both our human
fetal transplant with no cytoreduction and our human–
murine transplant with nonmyeloablative conditioning
suggest that a large single dose of HSCs can outcompete
recipient HSCs. This finding is in line with that of
Ramshaw et al. [30], i.e., that high levels of engraftment
were possible by a single infusion of marrow cells into nor-
mal unprepared mice. Limiting the number of transplants
performed prenatally should limit both the maternal and
fetal risk associated with the procedure. Although more
experimental data are needed, the opportunities to obtain a
massive number of human CD341 marrow cells from a sin-
gle donor for dose-response experimentation are restricted
because of their rarity and the ethics involved.
Although the feasibility of using high-dose purified
CD341 from adult donors to overcome HLA disparity has
been demonstrated in both preclinical and clinical studies
[31,32], GVHD remains a clinical problem if high purity of
CD341 cells cannot be consistently achieved. In baboon and
sheep fetuses given non–T cell-depleted mismatched adult
bone marrow, Roodman et al. [33] and Zanjani et al. [34]
described potential loss of chimeric recipients due to
GVHD. In this study, GVHD was not seen in the three
human fetuses and the seven human–murine chimeras after
transplantation of a large number of purified CD341 cells.
Our human–murine model was not identical to our
human–human in utero transplantations in several aspects.
First, human cytokines were given in the xenogeneic setting.
Second, these adult mice did not undergo the exponential
growth that the human fetuses had following transplantation.
Third, the mice received nonmyeloablative irradiation before
transplantation. Despite these disparities, we observed strik-
ing correlations between the levels of engraftment in the
three human fetuses and the seven human–murine chimeras
transplanted with the same human donor cells. For studies
that required a physiologically identical model, Archer et al.
[35] demonstrated the feasibility of murine–murine in utero
transplantation in NOD/SCID mice.
In summary, we have demonstrated the use of a feasible
small-animal model to test for the ideal dose of donor CD341
cells for human in utero transplantation. This model should
complement other animal models [33,36,37] and institutional
review board– and FDA-approved human clinical research
trials in the development of in utero transplants for a variety of
congenital nonimmunodeficiency disorders.
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